Trials / Completed
CompletedNCT04193436
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06835919 25 mg | PF-06835919 in 25 mg oral tablet will be administered on Day 1 |
Timeline
- Start date
- 2020-01-21
- Primary completion
- 2021-07-09
- Completion
- 2021-07-09
- First posted
- 2019-12-10
- Last updated
- 2024-02-16
- Results posted
- 2024-02-16
Locations
3 sites across 3 countries: Belgium, Czechia, Slovakia
Source: ClinicalTrials.gov record NCT04193436. Inclusion in this directory is not an endorsement.